ArticleThe Canadian journal of urology2025
Adverse histological features are more commonly observed in hypergonadotropic prostate cancer patients.
Article in The Canadian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome patients with prostate cancer have elevated gonadotropin levels. It is unknown, however, whether this condition directly influences carcinogenesis in the prostate. It is also unknown whether any specific hormone levels are useful to predict aggressive disease. The potential role of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in prostate physiology is widely discussed. The study aimed to evaluate whether patients with this endocrine pattern have different outcomes following radical prostatectomy.
methodsThis was a prospective cohort study of consecutive patients undergoing robot-assisted radical prostatectomy at the Andrology and Urology Department, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov (Moscow) from September to December 2023. After applying exclusion criteria, 60 patients were included and stratified into a hypergonadotropic cohort (upper tertile for LH and FSH; n = 14) and a control cohort (n = 46). Primary outcome was adverse histology defined as ISUP grade ≥ 3 on final pathology.
results10 of 14 hypergonadotropic patients (71.4%) and 15 of 46 patients in the control cohort (32.6%) had ISUP grade ≥ 3, and this difference was statistically significant (p = 0.014). The rate of T3 disease on pathology was 42.9% and 32.6% in hypergonadotropic patients and the control cohort, respectively (p = 0.532). No significant correlation was found between PSA and gonadotropin levels.
conclusionsPatients with prostate cancer may have elevated gonadotropin levels, potentially predicting aggressive disease. If validated, these findings could influence clinical decision-making in prostate cancer based on LH and FSH levels.
Indexed as
Identifiers
41496533What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.